Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.05.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Tommaso Lupia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, T-Lymphocytes, Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
T-cell redirecting therapies such as chimeric antigen receptor T-cells and bispecific antibodies, are emerging as a novel class of immunotherapeutic agents for treatment of relapsed refractory multiple myeloma (MM). Their use is associated with an increased risk of infectious adverse events, fostered by cytopenias, hypogammaglobulinemia and T-cell exhaustion. Multiple ongoing clinical trials and real-world studies are investigating safety of T-cell therapy, highlighting the need for strategies to prevent and monitor the risk of infection. Recommended measures for risk mitigation include intravenous immunoglobulin supplementation, adequate prophylaxis therapy, vaccination and careful assessment for early diagnosis and treatment of infection. Here, we summarize available data on the risk of infections with approved and under development T-cell redirecting therapies for the treatment of MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
- Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy.
- Department of Health Sciences, Division of Infectious Diseases, University of Genova, Genova, Italy; Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy; Division of Geographic Medicine and Infectious Disease, School of Medicine, Tufts University, Boston, MA.
- Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy. Electronic address: roberto.mina.rm@gmail.com.
Zitieren
APA
Lupia, T., Cani, L., Bringhen, S., De Rosa, F. G., Bruno, B., Mikulska, M., Corcione, S., & Mina, R. (2024). Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.002
Vancouver
Lupia T, Cani L, Bringhen S, De Rosa FG, Bruno B, Mikulska M, et al. Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.002
BibTeX
@article{Lupia2024,
author = {Lupia, Tommaso and Cani, Lorenzo and Bringhen, Sara and De Rosa, Francesco Giuseppe and Bruno, Benedetto and Mikulska, Malgorzata and Corcione, Silvia and Mina, Roberto},
title = {Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.05.002}
}
EUVIMED